An emerging biotech company turned to Calyx Medical Imaging after other centralized imaging providers failed to deliver reliable imaging services. They were looking for a partner to help them achieve high quality imaging data to support their studies’ primary endpoints. The studies – both focusing on novel therapies in rare disease – require qualitative assessments based on MRI images. In addition, one of the studies requires quantitative assessments based on advanced MRI techniques as well as TCD/TCDi. Taken together study eligibility, efficacy and / or safety will be supported by imaging.
The other providers couldn’t manage the complexity required by the study protocols and did not act as a true partner to the biotech company. As a result, the sponsor faced numerous risks, including inconsistent and poor-quality imaging, a lack of comprehensive imaging assessments/analysis, and limited scientific and operational expertise that would have impacted their development of novel compounds for the treatment of rare diseases.
The sponsor was not satisfied with the previous providers’ scientific and operational capabilities and hence was concerned with the realization of the studies’ endpoints:
> Imaging Acquisition Guidelines were convoluted without sufficient detail and difficult for the sites to adhere
> Site qualification and image quality control was not diligently performed
> Site communication was not comprehensive
Image Review and Analysis
> Lack of scientific and medical rigor in Independent Review Charter
> Insufficient guidance and monitoring of the independent readers
Utilizing our scientific and medical expertise, proven processes, experienced operational management, and robust systems, Calyx ensured a smooth transition and delivered:
Imaging Requirements and Guidelines
> Simplified, detailed, and streamlined Imaging Acquisition Guidelines to increase compliance, ensure quality, and reduce site burden
> 3-step site qualification process, which includes understanding site capabilities, training the site staff, and requiring a test scan
– Calyx’s ongoing relationship with the sites ensures good quality image acquisition without imposing additional burden to the site or patients
Independent Review Charter
> Fully re-written, comprehensive independent review charter including the MRI and TCD assessments, which enabled robust eCRFs to be developed and reviewer trainings to be conducted
> Calyx’s scientific and medical team is available for consulting to support protocol amendments, data interpretation, and any other questions that may arise throughout the study
The studies are now running efficiently, and Calyx is on track to deliver key imaging data to the sponsor, in line with their studies’ milestones. Feedback from the sponsor is the quality of the current imaging charter is significantly improved and they are confident that they will receive high quality imaging data to support their study endpoints.